**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Kwaku Appiah-Kubi, C. K. Tedam University of Technology and Applied Sciences, Navrongo, UK-0215-5321, Ghana

**Main Body of the Abstract**
This study seeks to substantiate reports on serum neurofilament light chain levels (sNfl)  as a diagnostic biomarker of ATTRv Amyloidosis. A comprehensive search on the PubMed database for relevant studies until January 2024. Human studies that contained baseline case-control data on sNfl in ATTRv Amyloidosis before treatment were included in the meta-analysis. The analysis compared sNfl levels in healthy subjects (HS) versus symptomatic ATTRv Amyloidosis patients (sATTRv), HS versus asymptomatic ATTRv Amyloidosis group (asATTRv), asATTRv versus sATTRv, and greater than I Polyneuropathy Disability (PND >1) score versus score I PND (PND I). The standard mean differences (SMD) at 95% confidence intervals (CI) were obtained using a random or fixed effects model of RevMan version 5.4.
A total of 589 sATTRv, 120 asATTRv, 67 PND >1, 45 with PND I score, and  4970 HS were meta-analyzed. The levels of sNfl were shown to be significantly higher in sATTRv than in HS (SMD=3.66, 95% CI: 0.99-5.73, PSMD=0.005), in sATTRv than in HS (SMD=1.77, 95% CI: 1.29-2.25, PSMD<0.00001), in PND >I than in PND I (SMD=1.39, 95% CI: 0.95-1.82, PSMD<0.00001), sNfl levels in HS and asATTRv yielded insignificantly negative SMD in asATTRv than in HS (SMD= -0.18, 95% CI: -1.12-0.76, PSMD=0.71) pointing to the fact that sNfl levels is a potent biomarker for early diagnosis of ATTRv Amyloidosis before symptoms of polyneuropathy manifest.
This study confirms sNfl as a potent biomarker for early diagnosis of ATTRv Amyloidosis; however, studies with larger sample sizes are needed to pave the way for an updated analysis.



Serum neurofilament light chain levels show promise as a biomarker for early detection and diagnosis of ATTRv Amyloidosis: A meta-analysis OC2 (#531)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.